# The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis

Study · id `cardio:ct-nct05350124` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05350124](<https://clinicaltrials.gov/study/NCT05350124>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05350124

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

## Technical summary

Registry record NCT05350124. Randomized; triple masking; primary purpose treatment. Start 2022-11 (anticipated); primary completion 2023-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT05350124, source copy `cardio:ctgov-nct05350124-2022-08-24`, retrieved 2026-10-26)
- Planned start: 2022-11 (anticipated) (ClinicalTrials.gov record NCT05350124, source copy `cardio:ctgov-nct05350124-2022-08-24`, retrieved 2026-10-26)
- Primary completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT05350124, source copy `cardio:ctgov-nct05350124-2022-08-24`, retrieved 2026-10-26)
- Completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT05350124, source copy `cardio:ctgov-nct05350124-2022-08-24`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05350124-2022-08-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Vitamin C and E Therapy on Restless Leg Syndrome in Patients With End Stage Renal Disease on Haemodialysis
- Condition: Restless Legs Syndrome
- Condition: End Stage Renal Disease
- Intervention (Drug): Ascorbic acid
- Intervention (Drug): Tocopherol
- Intervention (Drug): Placebo capsule
- Intervention (Drug): Placebo capsule
- Lead sponsor: King Abdulaziz University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 6bf0bd995a8968aa9c909e5d03ebe88e05254169a3a590a89f3a1810c22d8817
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
